Avibactam (AVI) — Competitive Intelligence Brief

Avibactam (AVI) (Avibactam (AVI)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactamase inhibitor. Area: Infectious Disease.

marketed Beta-lactamase inhibitor Serine beta-lactamases and metallo-beta-lactamases Infectious Disease Small molecule

Target snapshot

Avibactam (AVI) (Avibactam (AVI)) — Pfizer. Avibactam is a beta-lactamase inhibitor that protects beta-lactam antibiotics from enzymatic degradation by binding to and inactivating bacterial beta-lactamases.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Avibactam (AVI) TARGET	Avibactam (AVI)	Pfizer	marketed	Beta-lactamase inhibitor	Serine beta-lactamases and metallo-beta-lactamases
Piperacillin And Tazobactam	Piperacillin Sodium	Pfizer	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Bacterial cell wall; beta-lactamase enzyme	1981-01-01
Pipracil	Piperacillin Sodium	Pfizer Inc.	marketed	Penicillin-class antibacterial with beta-lactamase inhibitor	Beta-lactamase producing bacteria	1981-01-01
Co-amoxiclav	Co-amoxiclav	Imperial College London	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin potassium clavulanate	Amoxicillin potassium clavulanate	Kaizen Bioscience Co.	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Amoxicillin-Potassium Clavulanate Combination	Amoxicillin-Potassium Clavulanate Combination	Universidad Complutense de Madrid	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Imipenem, Cilastatin and Relebactam	Imipenem, Cilastatin and Relebactam	Joseph L. Kuti, PharmD	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); beta-lactamase inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactamase inhibitor class)

1. Pfizer · 1 drug in this class